Hyperlipidemia and mortality in patients on peritoneal dialysis

BMC Nephrology

Table 3 Association between hyperlipidemia and all-cause mortality using Cox proportional hazards regression

	Model 1		Model 2		Model 3		Model 4
	HR	95%CI	HR	95%CI	HR	95%CI	HR	95%CI
Over the overall follow-up period
Hyperlipidemia (yes/no)	1.52	1.23 to 1.86	1.02	0.82 to 1.26	1.03	0.83 to 1.29	1.04	0.83 to 1.31
From 48-month follow-up onwards
Hyperlipidemia (yes/no)	2.76	1.85 to 4.14	2.11	1.40 to 3.18	2.11	1.40 to 3.18	2.26	1.49 to 3.43

Model 1, unadjusted; model 2, model 1 plus age, sex, body mass index, systolic BP, diastolic BP, current smoking, current alcohol consumption, 24-hour urine volume, Charlson comorbidity index, diabetes mellitus, hypertension, and a history of CVD; model 3, model 2 plus calcium channel blockers, beta-blockers, ACEI/ARBs, diuretics, statins, and aspirin; model 4, model 3 plus hemoglobin, serum albumin, serum uric acid, eGFR, cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, and hs-CRP.
BP, blood pressure; CVD, cardiovascular disease; ACEI/ARBs, angiotensin II receptor blockers/angiotensin-converting enzyme inhibitors; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; HR, hazard ratio; CI, confidence interval

ISSN: 1471-2369